October 5, 2021
EPS Corporation
News Release

Web Seminar Held for Pharmaceutical Companies and Academic Institutions
Considering the Introduction of DDC*1
The EPS Corporation (Head Office: Shinjuku-ku, Tokyo; President and Representative Director:
Akira Sasa; hereinafter “EPS”) held Day 4 and Day 5 of its “Startup Guide to Quickly Grasp the Ins
and Outs of DCT*2 – Take Your First Step Toward DCT!” seminar series focusing on the topic of
DDC on August 24 and August 25, 2021.

This seminar generated a large amount of interest in both virtual/online clinical trials as well as
DDC with 465 people joining the seminar on Day 4 and 467 people on Day 5.
Over those two days, this basic DDC web seminar provided an overview of DDC and its core
concepts, the pros and cons of introducing DDC, regulatory and industry trends, and a wide rangeof other information.
As a result of a more practical and comprehensive look at DDC and an introduction to real-world
examples founded in the cumulative knowledge and experience about clinical studies gained by theEPS Data Management Department, a participant satisfaction survey showed a total of 77.88% onDay 4 and 85.13% on Day 5 were either “Very Satisfied” or “Satisfied” with this web seminar.

Q: How satisfied were you with the web seminar today?

Day4(8/24)

Day5(8/25)

EPS will also hold a “Follow-up Q&A Seminar” on October 26, 2021 to cover the many questions
received throughout this entire web seminar series from Day 1 to Day 5.
This follow-up seminar will consist of three sessions: ePRO*3/eCOA*4, eConsent*5/Online Medical
Examinations, and DDC. EPS plans to answer many of the questions it received on each of these
topics at each session.
Anyone who has not yet applied to join this seminar should feel free to register using the following
link (only Japanese):https://event.on24.com/wcc/r/3407554/5E8C496ECBF6D7B2FA8486896CE2BFFC
EPS is also advocating Virtual Go as a framework to promote virtual/online clinical trials as one
activity to make virtual/online clinical trials commonplace. In the future, EPS will continue to holdregular web seminars on this framework.
EPS Virtual Go Framework
As a leading company supporting clinical study work, EPS is advancing the Virtual Go framework
to promote virtual/online clinical trials using its wealth of expertise and experience in data science,
which is backed by an extensive track record.

Virtual Go is a generic name for all EPS services used to promote virtual/online clinical trials.
Virtual Go always strives to satisfy two core ideas: “virtual/online clinical trials in which patients
do not have to visit medical institutions” and “virtual/online clinical trials in which CRAs*6 do nothave to visit medical institutions.” To do this, EPS handles everything from the proposal tooperation and management of various schemes to advance virtual/online clinical trials right for thetrial design and type of disease. This includes eConsent, online medical examinations, DDC, eCOA,
the use of wearable devices, shipment of investigational product, home-visit nursing, and specimen
collection.
About EPS Corporation（https://www.eps.co.jp/en/）
EPS launched its business in 1991 as a CRO*7 to comprehensively support clinical studies with thefocus on clinical trials and PMS*8. The company proposes new models to satisfy customers’ needsby leveraging its data science expertise and digital technology cultivated through its extensive trackrecord. These proposals are founded in its Trial GATE concept, which acts as the gateway for all
promotion functions of clinical trials.
*1: DDC (Direct Data Capture)*5: eConsent (Electronic Consent)*2: DCT (Decentralized Clinical Trial)*6: CRA (Clinical Research Associate)*3: ePRO (Electronic Patient-Reported Outcomes)*7: CRO (Contract Research Organization)*4: eCOA (Electronic Clinical Outcome Assessment)*8: PMS (Post Marketing Surveillance)

Contact:
EPS Corporation
Administration Headquarters
General Affairs Office Public Relations
E-mail: koho@eps.co.jp